Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Heart and Vessels
Erschienen in:

27.02.2024 | Original Article

Clinical features, future cardiac events, and prognostic factors following percutaneous coronary intervention in young female patients

verfasst von: Yosuke Tatami, Akihito Tanaka, Taiki Ohashi, Ryuji Kubota, Shinji Kaneko, Masanori Shinoda, Yusuke Uemura, Kensuke Takagi, Miho Tanaka, Norio Umemoto, Hiroshi Tashiro, Naoki Shibata, Naoki Yoshioka, Masato Watarai, Itsuro Morishima, Yasunobu Takada, Kiyokazu Shimizu, Hideki Ishii, Toyoaki Murohara, N-registry investigators

Erschienen in: Heart and Vessels | Ausgabe 6/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

The proportion of young females among the patients who undergo percutaneous coronary intervention (PCI) is relatively small, and information on their clinical characteristics is limited. This study investigated the clinical characteristics and prognostic factors for future cardiac events in young females who underwent PCI.

Methods

This multicenter observational study included 187 consecutive female patients aged < 60 years who underwent PCI in seven hospitals. The primary composite endpoint was the incidence of cardiac death, nonfatal myocardial infarction, and target vessel revascularization.

Results

The mean patient age was 52.1 ± 6.1 years and 89 (47.6%) had diabetes, and renal dysfunction (an estimated glomerular filtration rate < 60 mL/min/1.73 m2) was observed in 38 (20.3%). During a median follow-up of 3.3 years, the primary endpoint occurred in 28 patients. The Cox proportional hazards models showed that renal dysfunction was an independent predictor for the primary endpoint (hazard ratio 3.04, 95% confidence interval 1.25–7.40, p = 0.01), as well as multivessel disease (hazard ratio 2.79, 95% confidence interval 1.12–6.93, p = 0.03). Patients with renal dysfunction had a significantly higher risk for the primary endpoint than those without renal dysfunction.

Conclusions

Renal dysfunction was strongly associated with future cardiac events in young females who underwent PCI.
Literatur
1.
Kubo M, Kiyohara Y, Kato I, Tanizaki Y, Arima H, Tanaka K, Nakamura H, Okubo K, Iida M (2003) Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama study. Stroke 34:2349–2354PubMedCrossRef
2.
Levy D, Wilson PW, Anderson KM, Castelli WP (1990) Stratifying the patient at risk from coronary disease: new insights from the Framingham Heart Study. Am Heart J 119:712–717PubMedCrossRef
3.
Chambless LE, Folsom AR, Sharrett AR, Sorlie P, Couper D, Szklo M, Nieto FJ (2003) Coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC) study. J Clin Epidemiol 56:880–890PubMedCrossRef
4.
Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350:1495–1504PubMedCrossRef
5.
SPRINT Research Group, Lewis CE, Fine LJ, Beddhu S, Cheung AK, Cushman WC, Cutler JA, Evans GW, Johnson KC, Kitzman DW, Oparil S, Rahman M, Reboussin DM, Rocco MV, Sink KM, Snyder JK, Whelton PK, Williamson JD, Wright JT Jr, Ambrosius WT (2021) Final Report of a Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 384:1921–1930CrossRef
6.
Japanese Coronary Artery Disease Study Investigators (2006) Current status of the background of patients with coronary artery disease in Japan. Circ J 70:1256–1262CrossRef
7.
Pagidipati NJ, Navar AM, Pieper KS, Green JB, Bethel MA, Armstrong PW, Josse RG, McGuire DK, Lokhnygina Y, Cornel JH, Halvorsen S, Strandberg TE, Delibasi T, Holman RR, Peterson ED, Tecos Study Group (2017) Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin). Circulation 136:1193–1203PubMedPubMedCentralCrossRef
8.
Sharabi Y, Grotto I, Huerta M, Eldad A, Green MS (2001) Risk factor profile for atherosclerosis among young adults in Israel–results of a large-scale survey from the young adult periodic examinations in Israel (YAPEIS) database. Eur J Epidemiol 17:757–764PubMedCrossRef
9.
Pelzer T, Shamim A, Neyses L (1996) Estrogen effects in the heart. Mol Cell Biochem 160–161:307–313PubMedCrossRef
10.
Skafar DF, Xu R, Morales J, Ram J, Sowers JR (1997) Clinical review 91: Female sex hormones and cardiovascular disease in women. J Clin Endocrinol Metab 82:3913–3918PubMed
11.
Trinder M, Francis GA, Brunham LR (2020) Association of Monogenic vs Polygenic Hypercholesterolemia With Risk of Atherosclerotic Cardiovascular Disease. JAMA Cardiol 5:390–399PubMedPubMedCentralCrossRef
12.
Hung J, Lam JY, Lacoste L, Letchacovski G (1995) Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Circulation 92:2432–2436PubMedCrossRef
13.
Liu R, Xu F, Zhou Y, Liu T (2020) The characteristics of risk factors in Chinese young women with acute coronary syndrome. BMC Cardiovasc Disord 20:290PubMedPubMedCentralCrossRef
14.
Arnold AZ, Moodie DS (1993) Coronary artery disease in young women: risk factor analysis and long-term follow-up. Cleve Clin J Med 60:393–398PubMedCrossRef
15.
Kolovou G, Kolovou V, Koutelou M, Mavrogeni S (2015) Atherosclerotic and Non-Atherosclerotic Coronary Heart Disease in Women. Curr Med Chem 22:3555–3564PubMedCrossRef
16.
Kurth J, Malik S (2015) Reducing women’s cardiovascular disease risk profile. Womens Health (Lond) 11:385–397PubMedCrossRef
17.
Negishi Y, Tanaka A, Ishii H, Takagi K, Inoue Y, Uemura Y, Umemoto N, Yoshioka N, Morishima I, Asano H, Watarai M, Shibata N, Suzuki S, Murohara T (2019) Contrast-Induced Nephropathy and Long-Term Clinical Outcomes Following Percutaneous Coronary Intervention in Patients With Advanced Renal Dysfunction (Estimated Glomerular Filtration Rate <30 ml/min/1.73 m(2)). Am J Cardiol 123:361–367PubMedCrossRef
18.
Yoshioka N, Takagi K, Morishima I, Morita Y, Uemura Y, Inoue Y, Umemoto N, Shibata N, Negishi Y, Yoshida R, Tanaka A, Ishii H, Murohara T, N-registry investigators (2019) Influence of Preadmission Frailty on Short- and Mid-Term Prognoses in Octogenarians With ST-Elevation Myocardial Infarction. Circ J 84:109–118PubMedCrossRef
19.
Shibata N, Umemoto N, Tanaka A, Takagi K, Iwama M, Uemura Y, Inoue Y, Negishi Y, Ohashi T, Tanaka M, Yoshida R, Shimizu K, Tashiro H, Yoshioka N, Morishima I, Noda T, Watarai M, Asano H, Tanaka T, Tatami Y, Takada Y, Ishii H, Murohara T, N-registry investigators (2021) Clinical Outcomes Following Emergent Percutaneous Coronary Intervention for Acute Total/Subtotal Occlusion of the Left Main Coronary Artery. Circ J 85:1789–1796PubMedCrossRef
20.
Inoue Y, Tanaka A, Asano H, Uemura Y, Takagi K, Ohashi T, Tanaka M, Umemoto N, Ajioka M, Tashiro H, Watarai M, Morishima I, Tatami Y, Takada Y, Shimizu K, Ishii H, Murohara T (2021) Clinical characteristics and treatment of Spontaneous Coronary Artery Dissection in Young Women Undergoing Percutaneous Coronary Intervention. J Cardiovasc Med (Hagerstown) 22:14–19PubMedCrossRef
21.
Yoshida R, Ishii H, Morishima I, Tanaka A, Takagi K, Yoshioka N, Kataoka T, Tashiro H, Hitora Y, Niwa K, Furusawa K, Morita Y, Tsuboi H, Murohara T (2020) Prognostic impact of recanalizing chronic total occlusion in non-infarct related arteries on long-term clinical outcomes in acute myocardial infarction patients undergoing primary percutaneous coronary intervention. Cardiovasc Interv Ther 35:259–268PubMedCrossRef
22.
Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD, ESC Scientific Document Group (2019) Fourth universal definition of myocardial infarction (2018). Eur Heart J 40:237–269PubMedCrossRef
23.
Ando K, Ishii K, Tada E, Kataoka K, Hirohata A, Goto K, Kobayashi K, Tsutsui H, Nakahama M, Nakashima H, Uchikawa S, Kanda J, Yasuda S, Yajima J, Kitabayashi H, Sakurai S, Nakanishi K, Inoue N, Noike H, Hasebe T, Sato T, Yamasaki M, Kimura T (2017) Prospective multi-center registry to evaluate efficacy and safety of the newly developed diamond-like carbon-coated cobalt-chromium coronary stent system. Cardiovasc Interv Ther 32:225–232PubMedCrossRef
24.
Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A, Collaborators developing the Japanese equation for estimated GFR (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53:982–992PubMedCrossRef
25.
Ando H, Yamaji K, Kohsaka S, Ishii H, Wada H, Yamada S, Sawano M, Inohara T, Numasawa Y, Ikari Y, Amano T, J-PCI Registry Investigators (2022) Japanese Nationwide PCI (J-PCI) Registry Annual Report 2019: patient demographics and in-hospital outcomes. Cardiovasc Interv Ther 37:243–247PubMedPubMedCentralCrossRef
26.
Ando H, Yamaji K, Kohsaka S, Ishii H, Sakakura K, Goto R, Nakano Y, Takashima H, Ikari Y, Amano T (2022) Clinical Presentation and In-Hospital Outcomes of Acute Myocardial Infarction in Young Patients: Japanese Nationwide Registry. JACC Asia 2:574–585PubMedPubMedCentralCrossRef
27.
Chronic Kidney Disease Prognosis C, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT (2010) Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 375:2073–2081CrossRef
28.
Best PJ, Lennon R, Ting HH, Bell MR, Rihal CS, Holmes DR, Berger PB (2002) The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 39:1113–1119PubMedCrossRef
29.
Yamagata K, Ishida K, Sairenchi T, Takahashi H, Ohba S, Shiigai T, Narita M, Koyama A (2007) Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int 71:159–166PubMedCrossRef
30.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group (2017) KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 7:1–59CrossRef
31.
Mizobuchi M, Towler D, Slatopolsky E (2009) Vascular calcification: the killer of patients with chronic kidney disease. J Am Soc Nephrol 20:1453–1464PubMedCrossRef
32.
Isakova T, Wahl P, Vargas GS, Gutierrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, Wolf M (2011) Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79:1370–1378PubMedPubMedCentralCrossRef
33.
Takayama Y, Yasuda Y, Suzuki S, Shibata Y, Tatami Y, Shibata K, Niwa M, Sawai A, Morimoto R, Kato S, Ishii H, Maruyama S, Murohara T (2016) Relationship between abdominal aortic and coronary artery calcification as detected by computed tomography in chronic kidney disease patients. Heart Vessels 31:1030–1037PubMedCrossRef
34.
Tatami Y, Yasuda Y, Suzuki S, Ishii H, Sawai A, Shibata Y, Ota T, Shibata K, Niwa M, Morimoto R, Hayashi M, Kato S, Maruyama S, Murohara T (2015) Impact of abdominal aortic calcification on long-term cardiovascular outcomes in patients with chronic kidney disease. Atherosclerosis 243:349–355PubMedCrossRef
35.
Hallan SI, Matsushita K, Sang Y, Mahmoodi BK, Black C, Ishani A, Kleefstra N, Naimark D, Roderick P, Tonelli M, Wetzels JF, Astor BC, Gansevoort RT, Levin A, Wen CP, Coresh J, Chronic Kidney Disease Prognosis Consortium (2012) Age and association of kidney measures with mortality and end-stage renal disease. JAMA 308:2349–2360PubMedPubMedCentralCrossRef
36.
Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, Scolari F, Schena FP, Remuzzi G (1999) Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354:359–364PubMedCrossRef
37.
Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, Renaal Study Investigators (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861–869PubMedCrossRef
38.
CONSENSUS Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316:1429–1435CrossRef
39.
Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S (2006) Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 368:581–588PubMedCrossRef
40.
Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC et al (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327:669–677PubMedCrossRef
41.
Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjostrom CD, Toto RD, Langkilde AM, Wheeler DC, Trial Committees Investigators DAPA-CKD (2020) Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 383:1436–1446PubMedCrossRef
42.
Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialist’s Consortium (2022) Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 400:1788–1801CrossRef
Metadaten
Titel
Clinical features, future cardiac events, and prognostic factors following percutaneous coronary intervention in young female patients
verfasst von
Yosuke Tatami
Akihito Tanaka
Taiki Ohashi
Ryuji Kubota
Shinji Kaneko
Masanori Shinoda
Yusuke Uemura
Kensuke Takagi
Miho Tanaka
Norio Umemoto
Hiroshi Tashiro
Naoki Shibata
Naoki Yoshioka
Masato Watarai
Itsuro Morishima
Yasunobu Takada
Kiyokazu Shimizu
Hideki Ishii
Toyoaki Murohara
N-registry investigators
Publikationsdatum
27.02.2024
Verlag
Springer Japan
Erschienen in
Heart and Vessels / Ausgabe 6/2024
Print ISSN: 0910-8327
Elektronische ISSN: 1615-2573
DOI
https://doi.org/10.1007/s00380-024-02369-7

Weitere Artikel der Ausgabe 6/2024

Comparison of left atrial appendage measurements between conventional transesophageal echocardiography and “Virtual TEE” reconstructed from computed tomography for pre-procedural planning of device closure

  • Original Article

Follistatin-like 1 (FSTL1) levels as potential early biomarker of cardiovascular disease in a Mexican population

  • Original Article

Impact of pemafibrate on lipid profile and insulin resistance in hypertriglyceridemic patients with coronary artery disease and metabolic syndrome

  • Original Article

Evaluating convolutional neural network-enhanced electrocardiography for hypertrophic cardiomyopathy detection in a specialized cardiovascular setting

  • Original Article

Flow pattern analysis of right ventricular outflow tract in repaired tetralogy of Fallot through 4D flow MRI

  • Original Article

Thirty-year outcomes of low-intensity anticoagulation for mechanical aortic valve

  • Original Article

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Kardiologie

Koronare Herzkrankheit: Das waren die Top-Studien 2024

Zum Thema Koronare Herzkrankheit gab es 2024 wichtige neue Studien. Beleuchtet wurden darin unter anderem der Stellenwert von Betablockern nach Herzinfarkt, neue Optionen für eine Lipidsenkung sowie die Therapie bei infarktbedingtem kardiogenem Schock.

Die elektronische Patientenakte kommt: Das sollten Sie jetzt wissen

Am 15. Januar geht die „ePA für alle“ zunächst in den Modellregionen an den Start. Doch schon bald soll sie in allen Praxen zum Einsatz kommen. Was ist jetzt zu tun? Was müssen Sie wissen? Wir geben in einem FAQ Antworten auf 21 Fragen.

Kaffeegenuss sicher bei Vorhofflimmern

Menschen mit Vorhofflimmern fürchten oft, Kaffee könnte schlecht für ihr Herz sein. Solche Ängste sind offenbar unbegründet: Zwei Schweizer Untersuchungen deuten sogar auf eine reduzierte Rate von kardiovaskulären Ereignissen unter Kaffeetrinkern.

Mit jedem Defibrillationsversuch sinkt die Überlebenschance

Wie wirkt es sich auf die Prognose aus, wenn bei Herzstillstand einmal, zweimal oder gar 29 Mal geschockt werden muss? Laut einer aktuellen Studie besteht ein deutlicher Zusammenhang zwischen der Zahl der Defibrillationsversuche und den Überlebenschancen.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Jetzt 10 CME-Punkte sammeln

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise